Bayer plans to divest household insecticides
No. 2 in the world, but no longer a core business
"In our Health Care business area, we now want to concentrate even more on our core competencies, which are researching, manufacturing and globally marketing human and animal health care products, as well as diagnostic systems," explained Bayer CEO Dr. Manfred Schneider. "Our world-renowned Baygon® and Autan® are no longer a good fit in this environment. They would have better growth prospects with a company specialized in such products."
The business unit's principal markets are in Asia and Latin America, while in the crucial North American and European markets it lacks the critical mass to capture market share from its much larger competitors. Bayer would need to invest heavily to continue growing this business, and such investment is not planned in view of the focus on other major areas in the future portfolio of Bayer HealthCare AG. To a suitable purchaser, however, the business offers significant potential for expansion, especially at the regional level.
Bayer aims to complete the sale by the end of 2002.
Most read news
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.